Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective

Experimental Biology and Medicine

Volumn 242, Issue 16, 2017, Pages 1579-1585

  Ewart, Lorna ^a   Fabre, Kristin ^a   Chakilam, Ananthsrinivas ^b   Dragan, Yvonne ^c   Duignan, David B ^d   Eswaraka, Jeetu ^e   Gan, Jinping ^f   Guzzie Peck, Peggy ^g   Otieno, Monicah ^g   Jeong, Claire G ^h   Keller, Douglas A ⁱ   de Morais, Sonia M ^d   Phillips, Jonathan A ^j   Proctor, William ^k   Sura, Radhakrishna ^d   Van Vleet, Terry ^d   Watson, David ^l   Will, Yvonne ^m   Tagle, Danilo ⁿ   Berridge, Brian ^h  

^a ASTRAZENECA   (United Kingdom)

^b VERTEX PHARMACEUTICALS   (United States)

^c Millennium: A Takeda Company   (United States)

^d ABBVIE INC   (United States)

^e AMGEN INC   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

^g API Large Molecule Pharmaceutical Development and Manufacturing Sciences   (United States)

^h GLAXOSMITHKLINE   (United States)

ⁱ SANOFI   (France)

^j BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^k GENENTECH INC   (United States)

^l ELI LILLY AND COMPANY   (United States)

^m PFIZER INC   (United States)

ⁿ NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

innovation; microphysiological systems; partnership; pharmacokinetics; Tissue chips; toxicology

Indexed keywords

CYTOKINE; NEW DRUG; TISSUE CHIP; TOXIC SUBSTANCE; UNCLASSIFIED DRUG;

CRISPR CAS SYSTEM; DECISION MAKING; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; DRUG SAFETY; HAZARD ASSESSMENT; HUMAN; NATIONAL HEALTH ORGANIZATION; NOTE; REPRODUCIBILITY; STEM CELL; LAB ON A CHIP; MICROCHIP ANALYSIS; MICROFLUIDICS; PRECLINICAL STUDY; PROCEDURES;

DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; LAB-ON-A-CHIP DEVICES; MICROCHIP ANALYTICAL PROCEDURES; MICROFLUIDICS;

EID: 85032338592     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370217715441     Document Type: Note

References (17)

1. McGonigle P, Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochem Pharmacol 2014; 87: 162–71.
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol 2014; 32: 760–72.
3. Esch EW, Bahinski A, Huh D. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov 2015; 14: 248–60.
4. Huh D, Leslie DC, Matthews BD, Fraser JP, Jurek S, Hamilton GA, Thornloe KS, McAlexander MA, Ingber DE. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci Trans Med 2014; 4: 1–8.
5. Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, Yuan H, Jiang D, Zhang D, Zangi L, Geva J, Roberts AE, Ma Q, Ding J, Chen J, Wang DZ, Li K, Wang J, Wanders RJ, Kulik W, Vaz FM, Laflamme MA, Murry CE, Chien KR, Kelley RI, Church GM, Parker KK, Pu WT. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med 2014; 20: 616–23.
6. Kim HJ, Lia H, Collins JJ, Ingber DE. Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc Natl Acad Sci USA 2015; 113: E7–15.
7. Laverty HG, Benson C, Cartwright EJ, Cross MJ, Garland C, Hammond T, Holloway C, McMahon N, Milligan J, Park BK, Pirmohamed M, Pollard C, Radford J, Roome N, Sager P, Singh S, Suter T, Suter W, Trafford A, Volders PGA, Wallis R, Weaver R, York M, Valentin J-P. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol 2011; 163: 675–93.
8. Berridge BR, Herman G, Van Vleet J, Cardiac, Vascular, and skeletal muscle systems. In: Haschek W, Rousseaux C, Wallig M, (eds). Haschek and Rousseaux’s handbook of toxicologic pathology, 3rd ed. NY: Elsevier Academic Press, 2013, pp. 1567–1657.
9. Materne E-M, Maschmeyer I, Lorenz AK, Horland R, Schimek KMS, Busek M, Sonntag F, Lauster R, Marx U. The multi-organ chip – a microfluidic platform for long-term multi-tissue coculture. J Vis Expt 2015; 98: e52526 1–11.
10. Oleaga O, Bernabini C, Smith AST, Srinivasan B, Jackson M, McLamb W, Platt V, Bridges R, Cai Y, Santhanam N, Berry B, Najjar S, Akanda N, Guo X, Martin C, Ekman G, Esch MB, Langer J, Ouedraogo G, Cotovio J, Breton L, Shuler ML, Hickman JJ. Multi-organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci Rep 2016; 6: 20030–20030.
11. Morton DM. Importance of species selection in drug toxicity testing. Toxicol Lett 1998; 102: 545–50.
12. Li AP. Accurate prediction of human drug toxicity: a major challenge in drug development. Chem Biol Interact 2004; 150: 3–7.
13. Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006; 2: 875–94.
14. Haney S, Jones B, Andersson L, Kodela K, Ewart L, Hamilton G. Development of rat, dog, and human liver-on-chip models that maintain long-term viability and CYP450 enzyme activity levels. 2015; Abstract at ISSX Florida meeting. Available at: http://issx.confex.com/issx/20NA/webprogram/Paper35184.html
15. Venetz D, Hess C, Lin CW, Aebi M, Neri D. Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies. Proc Natl Acad Sci 2015; 112: 2000–5.
16. Schadt S, Simon S, Kustermann S, Boess F, McGinnis C, Brink A, Lieven R, Fowler S, Youdim K, Ullah M, Marschmann M, Zihlmann C, Siegrist YM, Cascais AC, Di Lenarda E, Durr E, Schaub N, Ang X, Starke V, Singer T, Alvarez-Sanchez R, Roth AB, Schuler F, Funk C. Minimizing DILI risk in drug discovery – a screening tool for drug candidates. Toxicol In Vitro 2015; 30(1 Pt B): 429–37.
17. Sutherland JJ, Jolly RA, Goldstein KM, Stevens JL. Assessing concordance of drug induced transcriptional response in rodent liver and cultured hepatocytes. PLoS Comput Biol 2016; 12: e1004847–e1004847.